Drug
Bicalutamide clinical trials
Also written Casodex, ICI 176,334 and ICI 176334.
- studies test it
- 99
- open now
- 13
- in phase 3
- 26
- first study started
- 1994
Keep track of what changes. Save the bicalutamide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
98 studies that test it; most in 2001 (6)
| Year | Studies |
|---|---|
| 1994 | 1 |
| 1995 | 3 |
| 1996 | 1 |
| 1998 | 1 |
| 1999 | 1 |
| 2000 | 4 |
| 2001 | 6 |
| 2002 | 3 |
| 2003 | 5 |
| 2004 | 4 |
| 2005 | 4 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 26
- Phase 2
- 45
- Phase 3
- 26
- Phase 4
- 5
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 77
AstraZeneca (13) · Memorial Sloan Kettering Cancer Center (5) · Radiation Therapy Oncology Group (5) · European Organisation for Research and Treatment of Cancer - EORTC (3) · CHU de Quebec-Universite Laval (3) · Mayo Clinic (3) · NRG Oncology (2) · Alessa Therapeutics Inc. (2)
Often tested with
Tested in the same studies.
Goserelin (15) · Leuprolide (15) · Flutamide (10) · Triptorelin (6) · Degarelix (5) · Everolimus (5) · Ketoconazole (4) · Apalutamide (3)
Studies
Open first, then newest update. How each study uses bicalutamide is read from its arms, and is right about nine times in ten.
Testing it · 99
- A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07783282Written as bicalutamide
- A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder CancerRecruitingPhase 1University of Wisconsin, MadisonNCT05521698Written as Bicalutamide
- Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07593079Written as Bicalutamide
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTRecruitingPhase 2Baptist Health South FloridaNCT07455903Written as Bicalutamide
- Bicalutamide Therapy in Young Women With NAFLD and PCOSRecruitingPhase 1University of California, San FranciscoNCT05979389Written as Bicalutamide 50 mg
- Androgen-responsive POSLUMA-guided Intra-prostatic BoostRecruitingPhase 2Martin T. King, MD, PhDNCT07393867Written as Androgen Deprivation Therapy (ADT) +/- bicalutamide
- Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast CancerRecruitingPhase 1/2Icahn School of Medicine at Mount SinaiNCT05095207Written as Bicalutamide
- Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCCRecruitingPhase 1/2State University of New York at BuffaloNCT06222593Written as Bicalutamide in combination with Sunitinib
- Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast CancerRecruitingPhase 2Universitaire Ziekenhuizen KU LeuvenNCT06365788Written as Bicalutamide
- A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder CancerRecruitingPhase 2CHU de Quebec-Universite LavalNCT05327647Written as Bicalutamide
- SRT Versus SRT+ADT in Prostate CancerRecruitingPhase 3Marco Lorenzo BonuNCT05019846Written as Bicalutamide 50 mg
- Signal TrAnsduction Pathway Activity Analysis in OVarian cancERRecruitingPhase 2/3Gynaecologisch Oncologisch Centrum ZuidNCT03458221Written as Bicalutamide Oral Product
- The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2Not yet recruitingNot applicableRoyal College of Surgeons, IrelandNCT05647356Written as Bicalutamide 50 mg
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialActive, not recruitingPhase 3NRG OncologyNCT04513717Written as Bicalutamide
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingPhase 3NRG OncologyNCT05050084Written as Bicalutamide
- Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)Active, not recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT02605486Written as Bicalutamide
- High-Dose Brachytherapy in Treating Patients With Prostate CancerCompletedNot applicableStanford UniversityNCT02346253Written as Bicalutamide
- Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate CancerActive, not recruitingPhase 2City of Hope Medical CenterNCT00544830Written as Bicalutamide
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsActive, not recruitingPhase 2Providence Health & ServicesNCT03650894Written as Bicalutamide
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate CancerCompletedPhase 3Radiation Therapy Oncology GroupNCT00936390Written as bicalutamide
See all 99 studies that test bicalutamide →
Given in every arm · 49 — bicalutamide is usual care beside what is tested
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT03678025Written as Bicalutamide
- REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac TrialRecruitingPhase 3Emory UniversityNCT06650579Written as Bicalutamide
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerRecruitingPhase 2City of Hope Medical CenterNCT04734730Written as Bicalutamide
- Phase II Dutasteride in Combination With CAB vs CAB in SDCRecruitingPhase 2Radboud University Medical CenterNCT05513365Written as Bicalutamide 50 mg
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by SurgeryActive, not recruitingPhase 2/3NRG OncologyNCT03070886Written as Bicalutamide
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT01786265Written as Bicalutamide
- Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT01251861Written as Bicalutamide
- Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate CancerWithdrawnPhase 2OHSU Knight Cancer InstituteNCT06528210Written as Bicalutamide
- Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate CancerCompletedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT00328614Written as Total Androgen Suppression (TAS) with Bicalutamide
- Cabazitaxel With Radiation and Hormone Therapy for Prostate CancerCompletedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01420250Written as Anti-Androgen Therapy: Bicalutamide
- Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate CancerCompletedEarly Phase 1University of Wisconsin, MadisonNCT03358563Written as Bicalutamide
- Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate CancerCompletedPhase 1Medical University of South CarolinaNCT00099086Written as Bicalutamide
- Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate CancerCompletedPhase 1University of NebraskaNCT00482807Written as bicalutamide
- Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate CancerTerminatedPhase 3NCIC Clinical Trials GroupNCT00651326Written as bicalutamide
- Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate CancerWithdrawnPhase 2Eastern Cooperative Oncology GroupNCT00771017Written as bicalutamide
- Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of RelapseCompletedPhase 3UNICANCERNCT00055731Written as bicalutamide
- S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate CancerCompletedPhase 3SWOG Cancer Research NetworkNCT00004124Written as bicalutamide
- Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone MetastasesTerminatedPhase 2Ajjai Alva, MDNCT02582749Written as Bicalutamide
- Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & SurgeryStatus unknownPhase 2The Methodist Hospital Research InstituteNCT03541928Written as Bicalutamide
- Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate CancerCompletedPhase 3Radiation Therapy Oncology GroupNCT00004054Written as bicalutamide
Showing 20 of 49.
As the comparator · 15 — what is tested is compared with bicalutamide
- An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASActive, not recruitingPhase 3Aragon Pharmaceuticals, Inc.NCT02531516Written as Bicalutamide
- S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate CancerCompletedPhase 3SWOG Cancer Research NetworkNCT01809691Written as Bicalutamide
- A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following SurgeryActive, not recruitingPhase 2RTOG Foundation, Inc.NCT03809000Written as Bicalutamide
- A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate CancerCompletedPhase 2Astellas Pharma IncNCT01288911Written as bicalutamide
- Camostat With Bicalutamide for COVID-19TerminatedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04652765Written as Bicalutamide 150 mg
- LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate CancerCompletedPhase 2Barbara Ann Karmanos Cancer InstituteNCT02058706Written as bicalutamide
- Trial to Promote Recovery From COVID-19 With Endocrine TherapyWithdrawnPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04374279Written as Bicalutamide 150 Mg Oral Tablet
- A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate CancerActive, not recruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT03520478Written as Bicalutamide
- Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate CancerCompletedPhase 2PfizerNCT01664923Written as Bicalutamide
- TAK-700 in Castration Resistant Prostate CancerWithdrawnPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT01658527Written as Bicalutamide
- Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer PatientsCompletedPhase 3Ferring PharmaceuticalsNCT00884273Written as Bicalutamide
- Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate CancerTerminatedPhase 3Ferring PharmaceuticalsNCT00831233Written as Bicalutamide
- Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.CompletedPhase 2British Columbia Cancer AgencyNCT00757692Written as Bicalutamide
- Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate CancerCompletedPhase 3Ferring PharmaceuticalsNCT00833248Written as Bicalutamide
- Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate CancerCompletedPhase 3Speciality European Pharma LimitedNCT00841113Written as Goserelin plus Bicalutamide
Codes
What other systems call bicalutamide · ClinicalTrials.gg INT003346
- MeSH (NLM) C053541bicalutamideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) A0Z3NAU9DPBICALUTAMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 83008Confirmed FDA, Wikidata
- Wikidata Q1988832bicalutamideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1599BicalutamideOne source FDA
- DrugBank DB01128One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C053541 | bicalutamide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | A0Z3NAU9DP | BICALUTAMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 83008 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1988832 | bicalutamide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1599 | Bicalutamide | One source FDA |
| DrugBank | DB01128 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.